Actionable news
0
All posts from Actionable news
Actionable news in SELB: Selecta Biosciences Inc,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.72 to $9.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.72 to $9.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.75 to $9.735, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
4. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.85 to $9.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
5. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.83 to $9.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
6. LKST, Inc. is the general partner of Leukon. Timothy Springer is the president of LKST, Inc. and the managing member of TAS. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
7. Held by Leukon Investments LP ("Leukon").
8. Held by TAS Partners, LLC ("TAS").
Remarks:

More